|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||122.58 - 123.71|
|52-week range||104.50 - 128.17|
|Beta (5Y monthly)||0.22|
|PE ratio (TTM)||25.88|
|Forward dividend & yield||3.00 (2.43%)|
|Ex-dividend date||19 Apr 2021|
|1y target est||142.50|
What happened Shares of Seres Therapeutics (NASDAQ: MCRB) were soaring 17.1% higher as of 3:09 p.m. EDT on Wednesday. The big gain came after the company announced that it has achieved its target enrollment of 300 participants in a phase 3 study evaluating SER-109 in treating recurrent C.
ASBFY vs. NSRGY: Which Stock Is the Better Value Option?
Here's what you need to know as it played out on Thursday.